Adocia shares gained over 10% on Thursday morning on the Paris Bourse, following the biopharmaceutical company's announcement of positive results in the treatment of diabetes.

At around 9.15 am, the share price climbed by around 10% in volumes already double those of the previous day, making it by far the biggest gainer on the CAC Mid and Small index (-0.3%).

In a press release published early this morning, the company reported positive results from a Phase 1 study on BioChaperone Lispro with its Chinese partner Tonghua Dongbao.

The trial's primary endpoint was met, confirming the accelerated mechanism of action of BioChaperone Lispro compared with Humalog, Eli Lilly's flagship insulin.

BioChaperone Lispro is an ultra-rapid-acting insulin obtained by combining Adocia's proprietary technology with Humalog, the market-leading rapid-acting insulin.

Adocia emphasizes that the Phase 3 studies currently underway are the only remaining clinical activities prior to submission of a marketing authorization application to the Chinese regulatory authorities.

In this context, BioChaperone Lispro could become the first ultra-fast insulin marketed in China.

For the record, Adocia has licensed BioChaperone Lispro to Tonghua Dongbao for China, whose insulin market is worth over five billion dollars.

Despite today's spectacular rise, Adocia's share price is still down 61% for the year as a whole.

Copyright (c) 2022 CercleFinance.com. All rights reserved.